Faeth Therapeutics, Inc. Payments to Acquire Short-term Investments
Faeth Therapeutics, Inc. (FTH) reported Payments to Acquire Short-term Investments of $158.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-04
- Faeth Therapeutics, Inc. payments to acquire short-term investments for the quarter ending 2026-06-30 was $114.67M, a 4605.21% increase year-over-year.
- Faeth Therapeutics, Inc. payments to acquire short-term investments for the quarter ending 2026-03-31 was $43.89M, a 591.35% increase year-over-year.
- Faeth Therapeutics, Inc. payments to acquire short-term investments for the quarter ending 2025-12-31 was $6.52M, a 63.29% decline year-over-year.
- Faeth Therapeutics, Inc. payments to acquire short-term investments for the quarter ending 2025-09-30 was $9.85M, a 11.44% increase year-over-year.
- Faeth Therapeutics, Inc. payments to acquire short-term investments for fiscal 2025 was $25.16M, a 43.59% decline from fiscal 2024.
- Faeth Therapeutics, Inc. payments to acquire short-term investments for fiscal 2024 was $44.59M, a 110.86% increase from fiscal 2023.
- Faeth Therapeutics, Inc. payments to acquire short-term investments for fiscal 2023 was $21.15M, a 54.88% decline from fiscal 2022.
- Faeth Therapeutics, Inc. payments to acquire short-term investments for fiscal 2022 was $46.87M, a 74.48% decline from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $114.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $158.56M 10-Q · filed 2026-08-04 | $165.08M derived: sum of 3 quarters · filed 2026-08-04 | $174.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $43.89M 10-Q · filed 2026-05-15 | $50.42M derived: sum of 2 quarters · filed 2026-05-15 | $60.26M derived: sum of 3 quarters · filed 2026-05-15 | $62.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $16.37M derived: sum of 2 quarters · filed 2026-03-30 | $18.81M derived: sum of 3 quarters · filed 2026-08-04 | $25.16M 10-K · filed 2026-03-30 |
| 2025-09-30 | $9.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $12.28M derived: sum of 2 quarters · filed 2026-08-04 | $18.63M 10-Q · filed 2025-11-14 | $36.40M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $8.79M 10-Q · filed 2026-08-04 | $26.55M derived: sum of 3 quarters · filed 2026-08-04 | $35.39M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $6.35M 10-Q · filed 2026-05-15 | $24.11M derived: sum of 2 quarters · filed 2026-05-15 | $32.95M derived: sum of 3 quarters · filed 2026-05-15 | $44.69M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $17.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $26.60M derived: sum of 2 quarters · filed 2026-03-30 | $38.34M derived: sum of 3 quarters · filed 2026-03-30 | $44.59M 10-K · filed 2026-03-30 |
| 2024-09-30 | $8.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $20.57M derived: sum of 2 quarters · filed 2025-11-14 | $26.83M 10-Q · filed 2025-11-14 | $29.44M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $11.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $17.99M 10-Q · filed 2025-08-05 | $20.61M derived: sum of 3 quarters · filed 2025-08-05 | $29.29M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $6.26M 10-Q · filed 2025-05-06 | $8.87M derived: sum of 2 quarters · filed 2025-05-06 | $17.56M derived: sum of 3 quarters · filed 2025-05-06 | $17.56M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $11.30M derived: sum of 2 quarters · filed 2025-03-28 | $11.30M derived: sum of 3 quarters · filed 2025-03-28 | $21.15M 10-K · filed 2025-03-28 |
| 2023-09-30 | $8.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $8.69M derived: sum of 2 quarters · filed 2024-11-14 | $18.54M 10-Q · filed 2024-11-14 | $388.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $9.85M 10-Q · filed 2024-08-06 | -$8.30M derived: sum of 3 quarters · filed 2024-08-06 | $13.45M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $9.85M 10-Q · filed 2024-05-09 | -$8.30M derived: sum of 2 quarters · filed 2024-05-09 | $13.45M derived: sum of 3 quarters · filed 2024-05-09 | $48.70M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$18.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $3.60M derived: sum of 2 quarters · filed 2024-02-29 | $38.85M derived: sum of 3 quarters · filed 2024-02-29 | $46.87M 10-K · filed 2024-02-29 |
| 2022-09-30 | $21.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $57.00M derived: sum of 2 quarters · filed 2023-11-07 | $65.02M 10-Q · filed 2023-11-07 | $74.87M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $35.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $43.27M 10-Q · filed 2023-08-03 | $53.12M derived: sum of 3 quarters · filed 2023-08-03 | $79.79M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $8.02M 10-Q · filed 2023-05-09 | $17.87M derived: sum of 2 quarters · filed 2023-05-09 | $44.54M derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | $9.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $36.52M derived: sum of 2 quarters · filed 2023-03-29 | $183.67M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $26.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $173.82M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $147.15M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |